GO:0001962 alpha-1,3-galactosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001962 defines the enzymatic activity that transfers galactose to an acceptor oligosaccharide via an alpha-(1->3) linkage, producing the Galalpha1-3Gal epitope.
• The enzyme is encoded by GGTA1 in most mammals, but the gene is inactivated in humans and other catarrhines, leading to natural antibodies against the epitope.
• Alpha-1,3-galactosyltransferase is a Golgi-resident type II membrane protein that uses UDP-Gal or GDP-Gal as donor substrates.
• Knockout of GGTA1 in pigs is a cornerstone of xenotransplantation research to prevent hyperacute rejection.
• The enzyme's catalytic mechanism involves conformational gating and substrate-assisted catalysis, as revealed by recent structural studies.
• Research tools include CRISPR knockout, knock-in of humanized genes, and enzymatic assays using recombinant enzyme.
Description
Alpha-1,3-galactosyltransferase (EC 2.4.1.151) is a glycosyltransferase that catalyzes the transfer of galactose from a nucleotide sugar donor to an acceptor oligosaccharide, forming an alpha-(1->3) linkage. This activity is encoded by the GGTA1 gene in most mammals, but the gene is non-functional in humans and other catarrhine primates due to inactivating mutations. The resulting Galalpha1-3Gal epitope is a major xenoantigen, making this enzyme a central target in xenotransplantation research. Understanding its mechanism, regulation, and role in disease is critical for developing therapeutic strategies and for engineering cells and tissues for transplantation.
alpha-1,3-galactosyltransferase activity At A Glance
| GO ID | GO:0001962 |
|---|---|
| GO term | alpha-1,3-galactosyltransferase activity |
| Ontology | molecular_function |
| Synonym | isoglobotriaosylceramide synthase |
| Major function | Transfer of galactose to form alpha-(1->3) linkage on oligosaccharides |
| EC number | 2.4.1.151 |
| Substrates | UDP-galactose or GDP-galactose; acceptor oligosaccharide |
| Cellular location | Golgi apparatus membrane |
| Representative gene | GGTA1 (alpha-1,3-galactosyltransferase) |
What Is GO:0001962?
GO:0001962 alpha-1,3-galactosyltransferase activity is defined as the catalysis of the transfer of a galactose residue from a donor molecule, such as GDP-galactose or UDP-galactose, to an oligosaccharide, forming an alpha-(1->3) linkage. This activity is responsible for the synthesis of the Galalpha1-3Gal epitope, a carbohydrate structure found on glycolipids and glycoproteins of most mammals but absent in humans.
Why Is alpha-1,3-galactosyltransferase activity Important in Cell Biology?
Alpha-1,3-galactosyltransferase activity is critically important because it produces the Galalpha1-3Gal epitope, which is the primary xenoantigen responsible for hyperacute rejection in pig-to-human xenotransplantation. The absence of this enzyme in humans leads to the production of natural anti-Gal antibodies, which recognize the epitope and trigger complement-mediated lysis of graft cells. Consequently, knockout of GGTA1 in donor pigs has become a standard approach to overcome this barrier. Additionally, the enzyme is a model for studying glycosyltransferase mechanisms and for engineering glycans in biotechnology.
• Prevents hyperacute rejection in xenotransplantation by eliminating the Galalpha1-3Gal epitope.
• Serves as a target for genetic engineering of pigs to improve graft survival.
• Provides a model for understanding glycosyltransferase catalytic mechanisms.
• Enables synthesis of alpha-galactosylated glycoconjugates for research and therapeutic applications.
• Explains the evolutionary loss of the enzyme in humans and its immunological consequences.
• Facilitates studies of carbohydrate antigen-antibody interactions.
• Supports development of cell-based therapies and tissue engineering.
• Aids in the production of recombinant glycoproteins with defined glycan structures.
What Happens During alpha-1,3-galactosyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs a sugar donor and an acceptor molecule.
The enzyme binds a nucleotide sugar donor, typically UDP-galactose or GDP-galactose, and an acceptor oligosaccharide. The binding site accommodates the donor through specific interactions, and the acceptor is positioned for transfer.
Catalytic transfer and linkage formation
In simple terms: The enzyme attaches galactose to the acceptor with a specific 3D shape.
The galactose residue is transferred from the donor to the acceptor, forming an alpha-(1->3) glycosidic linkage. This reaction proceeds via a substrate-assisted catalytic mechanism, where the donor's phosphate group stabilizes the transition state.
Conformational gating
In simple terms: The enzyme changes shape to allow the reaction to happen.
Recent structural studies reveal that the enzyme undergoes donor-induced conformational gating, where binding of the donor triggers a conformational change that enables catalysis. This ensures specificity and prevents premature hydrolysis.
Product release and recycling
In simple terms: The finished product is released, and the enzyme is ready for another round.
After transfer, the alpha-galactosylated product is released, and the enzyme returns to its resting state. The nucleotide byproduct (UDP or GDP) is also released, allowing the enzyme to participate in multiple catalytic cycles.
Key Genes Involved in GO:0001962 alpha-1,3-galactosyltransferase activity
The following genes and proteins are directly involved in alpha-1,3-galactosyltransferase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GGTA1 | Encodes alpha-1,3-galactosyltransferase | Primary gene for knockout in xenotransplantation |
| B4GALT1 | Beta-1,4-galactosyltransferase | Related glycosyltransferase, potential compensatory pathway |
| A3GALT2 | Alpha-1,3-galactosyltransferase 2 | Isoglobotriaosylceramide synthase, similar activity |
| UDP-Gal | Donor substrate | Used in enzymatic assays |
| GDP-Gal | Alternative donor substrate | Used in enzymatic assays |
| Golgi apparatus | Location of enzyme activity | Target for subcellular localization studies |
| Anti-Gal antibodies | Immune recognition of product | Key factor in xenotransplantation rejection |
| Complement system | Mediates rejection | Downstream effector of anti-Gal antibodies |
| GGTA1 knockout pigs | Model for xenotransplantation | Preclinical and clinical studies |
| Human GGTA1 pseudogene | Inactivated gene | Evolutionary and immunological studies |
| Murine Ggta1 | Model enzyme | Alternative splicing studies |
| Recombinant GGTA1 | Enzyme for in vitro synthesis | Biocatalysis and glycan engineering |
| Alpha-gal epitope | Product of enzyme activity | Target for vaccines and diagnostics |
| Nucleotide sugar transporters | Supply substrates to Golgi | Indirect regulators of activity |
| Glycosphingolipids | Acceptor molecules | Substrates for isoglobotriaosylceramide synthesis |
| Glycoproteins | Acceptor molecules | Substrates for alpha-galactosylation |
How Is alpha-1,3-galactosyltransferase activity Regulated?
The activity of alpha-1,3-galactosyltransferase is regulated at multiple levels. Transcriptionally, the GGTA1 gene is expressed in a tissue-specific manner, with high levels in endothelial cells and other vascular tissues. The enzyme's localization to the Golgi apparatus is essential for its function, and its activity depends on the availability of nucleotide sugar donors, which are transported into the Golgi lumen. Additionally, the enzyme's catalytic activity can be modulated by conformational changes induced by substrate binding, as revealed by structural studies. In the context of xenotransplantation, the expression of GGTA1 is often manipulated through genetic engineering to reduce antigenicity.
alpha-1,3-galactosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GGTA1 | Xenotransplantation rejection | GGTA1 knockout pig (CRISPR) |
| GGTA1 | Alpha-gal syndrome | Mouse models with GGTA1 knockout |
| GGTA1 | Cancer immunotherapy | Tumor cells overexpressing GGTA1 |
| A3GALT2 | Isoglobotriaosylceramide synthesis | Knockout mice for A3GALT2 |
| Anti-Gal antibodies | Complement-mediated lysis | In vitro assays with human serum |
Xenotransplantation rejection
The presence of alpha-1,3-galactosyltransferase activity in pig tissues leads to the production of the Galalpha1-3Gal epitope, which is recognized by pre-existing natural antibodies in humans. This triggers hyperacute rejection of pig organ transplants. Knockout of GGTA1 in donor pigs eliminates this epitope and prevents antibody-mediated rejection, as demonstrated in recent clinical trials.
Autoimmune and inflammatory conditions
Anti-Gal antibodies, which are produced in response to the alpha-gal epitope, have been implicated in autoimmune diseases and inflammatory conditions. For example, the alpha-gal syndrome, an allergy to red meat, is associated with IgE antibodies against the epitope. Understanding the enzyme's activity helps in diagnosing and managing such conditions.
Cancer immunotherapy
The alpha-gal epitope has been explored as a target for cancer immunotherapy. Tumor cells engineered to express alpha-1,3-galactosyltransferase can be recognized by anti-Gal antibodies, leading to complement-mediated lysis and enhanced immune response. This approach is being investigated in preclinical models.
From alpha-1,3-galactosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GGTA1 knockout prevent hyperacute rejection? | GGTA1 knockout pig (CRISPR/Cas9) |
| What is the catalytic mechanism of alpha-1,3-galactosyltransferase? | Recombinant enzyme with point mutations |
| Can humanized GGTA1 reduce immunogenicity? | Knock-in of humanized GGTA1 in pig cells |
| How does alpha-gal epitope affect immune response? | Overexpression of GGTA1 in tumor cells |
| What are the isoforms of murine alpha-1,3-galactosyltransferase? | Alternative splicing variants in mice |
| Can alpha-1,3-galactosyltransferase be used for glycan engineering? | Recombinant enzyme in vitro |
How to Study the alpha-1,3-galactosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay with UDP-Gal | Transferase activity | Kinetic studies of recombinant enzyme |
| CRISPR knockout screen | Gene essentiality for epitope expression | Identifying regulators of glycosylation |
| X-ray crystallography | Three-dimensional structure | Mechanistic studies |
| Mass spectrometry | Glycan composition | Validation of knockout/knock-in |
| Flow cytometry with lectins | Cell surface alpha-gal epitope | Quantification of antigen expression |
| Western blot | Protein expression | Knockout validation |
| qRT-PCR | mRNA levels | Gene expression analysis |
Enzymatic activity assays
Alpha-1,3-galactosyltransferase activity can be measured using radioactive or fluorescent donor substrates (UDP-Gal or GDP-Gal) and acceptor oligosaccharides. The products are analyzed by chromatography or mass spectrometry.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes that regulate alpha-1,3-galactosyltransferase activity or the expression of the Galalpha1-3Gal epitope. Such screens are useful for discovering modulators of glycosylation pathways.
Structural biology
X-ray crystallography and cryo-electron microscopy can elucidate the three-dimensional structure of the enzyme, revealing conformational changes and catalytic mechanisms. These studies inform the design of inhibitors or engineered enzymes.
Glycan analysis
Mass spectrometry and lectin-based assays can detect the presence of alpha-galactosylated glycans on cell surfaces or secreted proteins. These methods are essential for validating knockout or knock-in models.
How CRISPR Can Be Used to Study GO:0001962 alpha-1,3-galactosyltransferase activity
Knockout
CRISPR/Cas9-mediated knockout of GGTA1 is widely used to eliminate alpha-1,3-galactosyltransferase activity in pig cells and animals, preventing the synthesis of the Galalpha1-3Gal epitope and reducing xenotransplant rejection. Knockout models are also used to study the enzyme's role in glycosphingolipid synthesis.
Point Mutation
Point mutations can be introduced into the catalytic domain of GGTA1 to dissect the mechanism of substrate binding and catalysis. For example, mutations in the donor-binding site can abolish activity, while mutations in the acceptor-binding site can alter specificity.
Knock-in
Knock-in of humanized GGTA1 or other glycosyltransferases can be used to modify the glycan profile of cells. This approach is used to create cells with reduced immunogenicity for transplantation or to produce specific glycoforms of therapeutic proteins.
Overexpression
Overexpression of GGTA1 in cells that normally lack the enzyme (e.g., human cells) can be used to study the effects of the alpha-gal epitope on immune recognition and cell signaling. This is particularly useful in cancer immunotherapy research.
How EDITGENE Supports alpha-1,3-galactosyltransferase activity Research
Researchers studying alpha-1,3-galactosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosylation, immune recognition, or xenotransplantation rejection. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for alpha-1,3-galactosyltransferase activity research.
Frequently Asked Questions About alpha-1,3-galactosyltransferase activity
What is alpha-1,3-galactosyltransferase activity?
It is the enzymatic activity that transfers galactose to an oligosaccharide, forming an alpha-(1->3) linkage, encoded by the GGTA1 gene in most mammals.
What genes are involved in alpha-1,3-galactosyltransferase activity?
The primary gene is GGTA1, but related genes like A3GALT2 and B4GALT1 may also contribute to glycosylation pathways.
Why is alpha-1,3-galactosyltransferase important in xenotransplantation?
It produces the Galalpha1-3Gal epitope, which triggers hyperacute rejection of pig organs in humans; knockout of GGTA1 prevents this.
What is the GO term for alpha-1,3-galactosyltransferase activity?
The GO ID is GO:0001962, under molecular_function ontology.
How is alpha-1,3-galactosyltransferase activity measured?
It can be measured using enzymatic assays with UDP-Gal or GDP-Gal and acceptor substrates, followed by chromatographic or mass spectrometric analysis.
What are the substrates of alpha-1,3-galactosyltransferase?
The donor substrates are UDP-galactose or GDP-galactose, and the acceptor is an oligosaccharide, often on glycoproteins or glycolipids.
Is alpha-1,3-galactosyltransferase present in humans?
No, the gene is inactivated in humans and other catarrhine primates, leading to the absence of the Galalpha1-3Gal epitope.
What diseases are associated with alpha-1,3-galactosyltransferase?
It is associated with xenotransplantation rejection, alpha-gal syndrome, and potential cancer immunotherapy applications.
How can CRISPR be used to study alpha-1,3-galactosyltransferase?
CRISPR can knock out GGTA1 to eliminate the epitope, introduce point mutations to study catalysis, or knock in humanized genes to reduce immunogenicity.
What model organisms are used to study alpha-1,3-galactosyltransferase?
Pigs, mice, and cell lines are commonly used, with GGTA1 knockout pigs being the most relevant for xenotransplantation.
Conclusion
Alpha-1,3-galactosyltransferase activity (GO:0001962) is a key enzymatic function that generates the Galalpha1-3Gal epitope, a major barrier in xenotransplantation. Its absence in humans and the resulting immune response have driven the development of GGTA1 knockout pigs, which are now in clinical trials. Beyond transplantation, the enzyme serves as a model for glycosyltransferase mechanisms and a tool for glycan engineering. Continued research using CRISPR and other genetic tools will further elucidate its roles in health and disease.
References
- 1. Montgomery RA et al.. 2022. Results of Two Cases of Pig-to-Human Kidney Xenotransplantation.. N Engl J Med 386(20):1889-1898 PMID: 35584156
- 2. Yamada K et al.. 2017. Tolerance in xenotransplantation.. Curr Opin Organ Transplant 22(6):522-528 PMID: 28937406
- 3. Montgomery RA et al.. 2026. Physiology and immunology of a pig-to-human decedent kidney xenotransplant.. Nature 650(8100):218-229 PMID: 41233546
- 4. Tearle RG et al.. 1996. The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation.. Transplantation 61(1):13-9 PMID: 8560551
- 5. Linares-Pastén JA et al.. 2026. Donor-induced conformational gating and substrate-assisted catalysis in α-1,3-galactosyltransferase.. Protein Sci 35(9):e70770 PMID: 42603117
- 6. Galili U et al.. 1991. Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys.. Proc Natl Acad Sci U S A 88(16):7401-4 PMID: 1908095
- 7. Joziasse DH et al.. 1992. Murine alpha 1,3-galactosyltransferase. A single gene locus specifies four isoforms of the enzyme by alternative splicing.. J Biol Chem 267(8):5534-41 PMID: 1544928
- 8. Joziasse DH et al.. 1990. Alpha 1----3-galactosyltransferase: the use of recombinant enzyme for the synthesis of alpha-galactosylated glycoconjugates.. Eur J Biochem 191(1):75-83 PMID: 2116309
